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Abstract 
Background: Venous thromboembolic co‑morbidities can have a significant impact on treatment response, treat‑
ment options, quality of life, and ultimately, survival from cancer. There is a dearth of published information on venous 
thromboembolic co‑morbidity among older soft tissue sarcoma patients.
Methods: SEER‑Medicare linked data (1993–2005) was utilized for this retrospective cohort analysis (n = 3,480 soft 
tissue sarcoma patients). Non‑cancer patients were frequency‑matched by age to cancer patients at a ratio of 1:1; 
coverage and follow‑up requirements were the same as for soft tissue sarcoma cases. Venous thromboembolic events 
were divided into three groups of interest: deep vein thrombosis, pulmonary embolism, and other thromboembolic 
events. Relative incidence rates of venous thromboembolic events in soft tissue sarcoma patients with a recent 
history of cardiovascular event or venous thromboembolic event (12 months before diagnosis) versus soft tissue 
sarcoma patients without such a recent history were calculated using the Cox proportional hazard models. The Cox 
proportional hazard model was used to build predictive models to identify important risk factors for each venous 
thromboembolic event of interest among soft tissue sarcoma patients. Relative incidence rate of VTEs in cancer 
patients (12 months after diagnosis) versus non‑cancer cases (12 months after index date) was calculated using multi‑
variable Cox proportional hazard models.
Results: We observed that among older soft tissue sarcoma patients, 10.6% experienced a deep vein thrombosis, 
3.0% experienced a pulmonary embolism, and 3.1% experienced other thromboembolic events in the 12 months 
after sarcoma diagnosis. On average, 60% of venous thromboembolic events occurred in the first 90 days after sar‑
coma diagnosis. The highest rates of deep vein thrombosis and pulmonary embolism after sarcoma diagnosis were 
seen in patients with sarcoma not otherwise specified (deep vein thrombosis: 204/1,000 p‑y and pulmonary embo‑
lism: 50/1,000 p‑y). Recent history of a venous thromboembolic event was the strongest predictor of a subsequent 
venous thromboembolic event after soft tissue sarcoma diagnosis.
Conclusion: Venous thromboembolic events are common and serious co‑morbidities that should be closely moni‑
tored in older soft tissue sarcoma patients.
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Background
Venous thromboembolic co-morbidities among cancer 
patients can have a significant impact on quality of life, 
treatment options, treatment response, and ultimately, 
survival from cancer [1–3]. A small body of evidence is 
developing for brain, breast, lung, ovarian, and pancreatic 
cancers, suggesting that the incidence of venous throm-
boembolic events (VTEs) VTEs varies substantially by 
cancer subtype [2, 4–13]. Estimates for the occurrence 
of VTEs in these cancers range from as low as 0.4% up 
to 26.0%, depending on the cancer type, study popula-
tion, and the length of follow-up [12]. Because the risk of 
VTEs differs by the histological type of each cancer, it is 
important to carefully characterize this co-morbidity by 
cancer subtype.
There is a dearth of information on the extent of venous 
thromboembolic co-morbidity among older soft tissue 
sarcoma (STS) patients in the literature. VTE incidence 
among STS patients has rarely been addressed, timing of 
VTEs has not been investigated, co-factors have not been 
considered, soft tissue and bone sarcomas are usually 
combined, and older populations have not been studied. 
It is important to understand the scope of VTEs, before 
and after diagnosis, in order to offer STS patients optimal 
care and improved quality of life.
The main goals of this study were (1) to estimate the 
incidence of VTEs before STS diagnosis and during 
90-day time periods after STS diagnosis and (2) to pro-
duce adjusted relative risk estimates of VTEs for STS 
patients with and without a cardiovascular disease or 
VTE history and (3) to compare risk of VTEs for STS 
patients versus age-matched non-cancer individuals.
Methods
Study population
SEER-Medicare data is a linkage of US cancer regis-
try data with Medicare claims data. This database com-
bines two large, population-based, geographically diverse 
US data sources, providing detailed information about 
older persons (≥65 years) with and without cancer. Data 
from 1993 to 2005 were utilized for this retrospective 
cohort analysis. Patients 65  years of age and over who 
were diagnosed with STS and had at least 24  months 
of continuous non-HMO Medicare coverage (Parts A 
and B) before diagnosis and 1–12  months of follow-up 
information after diagnosis were included in the cancer 
cohort. Duration of patient follow-up after diagnosis 
(maximum 12 months) was the number of months until 
the patient died or lost Medicare coverage. If neither 
of these events occurred before the end of the planned 
follow-up time after diagnosis, the patient was followed 
for the full 12  months. Non-cancer patients were fre-
quency-matched by age to cancer patients at a ratio of 
1:1; and coverage and follow-up requirements were the 
same as for STS cases. VTEs of interest were deep vein 
thrombosis (DVT), pulmonary embolism (PE), and other 
thromboembolic events (OTE). Thromboembolic events 
included in the OTE category were as follows: central 
retinal vein occlusion, venous tributary (branch) occlu-
sion, nonpyogenic thrombosis of intracranial venous 
sinus, phlebitis/thrombophlebitis of superficial veins of 
lower and upper extremities, phlebitis/thrombophlebitis 
of other sites, gout with other specified manifestations, 
Budd–Chiari syndrome, venous embolism/thrombosis 
of renal vein, and portal vein thrombosis. ICD-9 diagno-
sis codes were used to identify VTEs and ICD-O-3 codes 
were used to identify STS patients (overall and by sub-
type). Types and definitions of STS by ICD-O-3 histology 
codes are as follows: GIST (8935, 8936), leiomyosarcoma 
(8890–91, 8894–97), malignant fibrous histiocytoma 
(8830), liposarcoma (8850–8855, 8858), dermatofibro-
sarcoma (8832, 8833), rhabdomyosarcoma (8900–8902, 
8910, 8912, 8920), angiosarcoma (9120, 9130, 9133, 
9170), nerve sheath tumor (9540, 9560–62), fibrosar-
coma (8810, 8811, 8814, 8815), sarcoma NOS (not 
otherwise specified) (8800–8805), Ewing Sarcoma/primi-
tive neuroectodermal tumor (9260, 9364, 9365, 9473), 
extraskeletal osteosarcoma (9180, 9181), extraskeletal 
chondrosarcoma (9220, 9231, 9240), synovial sarcoma 
(9040–9043), clear cell sarcoma (9044), myxosarcoma 
(8840), malignant hemangiopericytoma (9150), malig-
nant giant cell tumor (9251, 9252), malignant granular 
cell tumor (9580), alveolar soft part sarcoma (9581), and 
desmoplastic small round cell tumor (8806). Bone and 
joint sites were excluded for all above mentioned diag-
noses as were non-malignant tumor types. DVT was 
captured using ICD-9 codes of 451.1 (451.11, 451.19) 
451.2, 451.81, 451.83, 451.84, 453.1, 453.2, 453.4 (453.40, 
453.41, 453.42) 453.8, and 453.9; PE was captured using 
ICD-9 codes of 415.1 and 415.19; and OTEs were cap-
tured using ICD-9 codes of 362.35, 362.36, 437.6, 451.0, 
451.82, 451.89, 451.9, 453.0, 453.3, and 452.
Statistical analysis
STS patients
Incidence rates of each VTE (a) in the 12 months before 
diagnosis and (b) in the 12 months after diagnosis were 
described by age, race, sex, stage at diagnosis, and year 
of diagnosis. The numerator is the number of events 
that occurred over the respective 12-month period and 
the denominator was the person-years at risk. Events in 
the 12  months after diagnosis were further described 
as the proportion of cases with a first event in discrete 
time intervals of follow-up time (0–90 days, 91–180 days, 
181–270 days, and 271–365 days). The numerator of each 
incidence proportion is the number of persons with their 
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first event of interest during that time period only, while 
the denominator represents the persons who were alive 
and free of events at the beginning of the period.
Relative incidence rates of VTEs in STS patients with 
a recent history of cardiovascular event (CV) or VTE 
event (12  months before diagnosis) versus STS patients 
without such a recent history were calculated using the 
Cox proportional hazard models. Using a commonly 
used definition present in the literature, history of CV 
event was defined as any of the following events in the 
12  months before STS diagnosis: myocardial infarc-
tion, ischemic stroke, congestive heart failure, angina, 
or TIA in the prior 12  months. The first VTE outcome 
was counted for each patient from time of diagnosis up to 
12 months after diagnosis. Potential confounders, identi-
fied through ICD-9 diagnosis and procedure codes, were 
as follows: age at diagnosis, race, sex, diabetes, hypercho-
lesterolemia, atherosclerosis, varicose veins, recent high-
risk surgical procedure, central venous catheter, kidney 
disease, stage at diagnosis, surgery of primary tumor, 
chemotherapy, history of cancer. Results are presented by 
major STS subtypes [angiosarcoma, fibrosarcoma, GIST, 
leiomyosarcoma, liposarcoma, malignant fibrous histio-
sarcoma (MFH), nerve sheath tumor, and sarcoma NOS] 
where cell sizes permit.
The Cox proportional hazard model was used to build 
predictive models to identify important risk factors for 
each VTE of interest among STS patients. Potential risk 
factors included in the initial (full) model were as fol-
lows: age at diagnosis, race, sex, diabetes, hypercholester-
olemia, atherosclerosis, varicose veins, recent high-risk 
surgical procedure, central venous catheter, kidney dis-
ease, stage at diagnosis, chemotherapy, hormone therapy, 
surgery of primary tumor, history of cancer, and recent 
history of VTE of interest. After stepwise backwards 
elimination, risk factors with a multivariable p value <0.1 
were retained in the final multivariable predictive model.
STS vs. non‑cancer patients
A matched-cohort design was utilized to evaluate the rel-
ative incidence rate of VTEs in STS patients (12 months 
before diagnosis) versus non-cancer cases (12  months 
before index date). Multivariable logistic regression mod-
eling was performed. Potential confounders assessed 
were as follows: race, sex, diabetes, hypercholesterolemia, 
atherosclerosis, varicose veins, recent high-risk surgical 
procedure, central venous catheter, kidney disease, recent 
history of cardiovascular or VTEs. All models were 
adjusted for age to account for the age-matched design.
Relative incidence rate of VTEs in cancer patients 
(12  months after diagnosis) versus non-cancer cases 
(12 months after index date) was calculated using multi-
variable Cox proportional hazard models. Matching was 
accounted for by including the matching variable (age) in 
the STRATA statement. Potential confounders assessed 
were the same as in aforementioned logistic regression 
models. Where possible, results are presented by major 
STS subtypes [angiosarcoma, fibrosarcoma, GIST, leio-
myosarcoma, liposarcoma, malignant fibrous histiosar-
coma (MFH), nerve sheath tumor, sarcoma NOS]. Sas 9.1 
was used to perform all analyses.
Results
The study population for the first series of analyses con-
sisted of 3,480 STS patients 65  years of age and older 
(median age  =  77). Eighty-five percent of the popula-
tion was white, 9% of the population was black, and 6% 
was another race. Forty-seven percent of STS patients 
were male. The distribution of cases by stage was as fol-
lows: 43% localized, 23% regional, 21% distant, and 14% 
unstaged. The most common STS subtypes in our data 
were sarcoma NOS (40.9%), GIST (24.3%), leiomyo-
sarcoma (7.6%), MFH (6.4%), and angiosarcoma (5.3%) 
(Table 1). The two most common primary sites were con-
nective or subcutaneous tissue (35.0%) and the digestive 
system (31.8%) (Table  1). The non-cancer comparison 
cohort (n = 3,480) was similar in its distribution of age, 
race, and sex (Table 1).
STS patients
Among STS patients, DVTs occurred at the highest rate 
(149/1,000  person-years) of all VTEs after diagnosis 
(Table  2). The unadjusted incidence rate of VTEs was 
1.7–4.1 times higher during the 12-month period after 
STS diagnosis than the 12-month period prior to cancer 
diagnosis (Table 2). Regardless of VTE type, over half of 
VTEs occurred in the first 90  days after STS diagnosis: 
DVT: 62% (228/367), PE: 67% (70/105), and OTE: 51% 
(55/108). This pattern did not vary by STS subtype (data 
not shown).
When STS cases were stratified further by subtype, the 
highest rates of DVT and PE were seen in sarcoma NOS 
patients (DVT: 204/1,000 p-y and PE: 50/1,000 p-y). Rates 
of OTEs ranged from 18/1,000 to 50/1,000; however, 
estimates for most subtypes were based on very small 
numbers (Table  3). Unadjusted analyses revealed that 
STS patients with a recent history of a VTE had substan-
tially higher rates of that specific VTE after STS diagno-
sis than those without history of that VTE (Table 3). STS 
patients with a recent history of a CVD event had slightly 
higher rates of VTEs after STS diagnosis than those 
without history of a CVD event. Patients of advanced or 
regional STS stage had higher rates of VTEs after diagno-
sis compared to patients with localized disease. Patients 
who were treated with chemotherapy were also more 
likely compared to patients without chemotherapy to 
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experience a VTE after STS diagnosis. Patients who were 
treated with surgery of their primary tumor were half as 
likely as patients without surgery to experience a VTE 
after STS diagnosis.
Multivariable modeling was conducted to more closely 
evaluate the association between VTE history and incidence 
of VTEs after sarcoma diagnosis by STS subtype. Overall, 
history of a VTE in the 12 months before sarcoma diagno-
sis substantially increased the risk of a subsequent VTE in 
the 12 months after STS diagnosis (HR range = 6.4–49.3) 
(Table  4). Although all age-adjusted associations were 
strong, the most marked associations were seen in patients 
with leiomyosarcoma (HR =  49.3, 95% CI =  22.2–109.0), 
GIST (HR =  20.9, 95% CI =  13.6–32.2), and liposarcoma 
(HR = 19.1, 95% CI = 4.2–87.4) (Table 4).
Predictors of each VTE subtype after sarcoma diag-
nosis were evaluated among the combined group of STS 
patients. There were only two statistically significant pre-
dictors of increased risk of PE after STS diagnosis: ath-
erosclerosis and recent history of PE. There were four 
predictors of increased risk of OTE after STS diagnosis: 
atherosclerosis, hormone therapy, recent history of OTE 
and varicose veins. There were multiple predictors of 
both increased risk and decreased risk of DVT among the 
combined group of STS patients. Predictors of increased 
risk of DVT included kidney disease, radiation treatment, 
regional or distant stage and varicose veins; predictors 
of decreased risk of DVT included surgery of primary, 
high risk surgery, and central venous catheter. By far, 
the strongest predictor of all VTE events after STS diag-
nosis was a history of that same event in the 12 months 
before diagnosis (DVT: HR  =  7.6, 95% CI  =  5.7–10.1; 
PE: HR = 17.6, 95% CI = 9.4–33.0; OTE: HR = 16.6, 95% 
CI = 10.8–25.4) (data not shown). Presence of atheroscle-
rosis was also an important predictor for all VTE events, 
associated with a 1.8–2.5 times greater risk of VTE (DVT: 
HR = 1.8, 95% CI = 1.4–2.3; PE: HR = 2.0, 95% CI = 1.3–
3.1; OTE: HR = 2.5, 95% CI = 1.7–3.8) (data not shown).
STS patients compared to an age‑matched, non‑cancer 
population
Angiosarcoma and sarcoma NOS patients were more 
likely to have experienced a VTE in the recent past 
Table 1 SEER-Medicare study population (1993–2005): 
soft tissue sarcoma patients (n =  3,480) and  non-cancer 
controls (n = 3,480)
Cancer Non‑cancer
n % N %
Age in years
 65–69 475 13.7 549 15.8
 70–74 825 23.7 836 24.0
 75–79 880 25.3 853 24.5
 80–84 744 21.4 715 20.6
 85+ 556 16.0 527 15.1
Race
 Black 300 8.6 301 8.7
 White 2,967 85.3 2,945 84.6
 Other/unknown race 213 6.1 234 6.7
Sex
 Female 1,843 53.0 1,972 56.7
 Male 1,637 47.0 1,508 43.3
STS subtype
 Sarcoma NOS 1,422 40.9 na na
 GIST 845 24.3 na na
 Leiomyosarcoma 264 7.6 na na
 Maligant fibrous histiocytoma 224 6.4 na na
 Angiosarcoma 184 5.3 na na
 Liposaroma 136 3.9 na na
 Nerve sheath tumor 118 3.4 na na
 Fibrosarcoma 64 1.8 na na
 Synovial Sarcoma 49 1.4 na na
 Osteosarcoma 44 1.3 na na
 Rhabdomyosarcoma 25 0.7 na na
 Chondrosarcoma 25 0.7 na na
 Dermatofibrosaroma 22 0.6 na na
 Ewing sarcoma 19 0.5 na na
 Maligant hemangiopericytoma 15 0.4 na na
 Clear cell sarcoma <11 0.3 na na
 Myxosarcoma <11 0.2 na na
 Alveolar soft part <11 0.1 na na
 Maligant granular cell tumor <11 0.1 na na
 Maligant giant cell tumor <11 0.0 na na
Primary site
 Connective/subcutaneous tissue 1,217 35.0 na na
 Digestive system 1,107 31.8 na na
 Respiratory system 279 8.0 na na
 Breast 178 7.7 na na
 Other non‑epithelial skin 167 5.1 na na
 Female genital system 160 4.8 na na
 Urinary system 105 4.6 na na
 Other and unknown 267 3.0 na na
Stage
 Unstaged 482 13.9 na na
 Localized 1,482 42.6 na na




n % N %
 Regional 800 23.0 na na
 Distant 716 20.5 na na
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(i.e. 12  month prior to STS diagnosis/index date) than 
non-cancer individuals (Table  5). A strong association 
between STS and VTE after diagnosis (or index date for 
non-cancer patients) was observed in most STS subtypes. 
The strongest comparisons of VTE after diagnosis for 
cancer versus non-cancer patients were among angio-
sarcoma (HR  =  9.1, 95% CI  =  2.1–39.5), leiomyosar-
coma (HR = 5.5, 95% CI = 2.1–15.0) and sarcoma NOS 
patients (HR = 5.2, 95% CI = 3.8–6.9) (Table 5).
Discussion
We studied the incidence of venous thromboembolic 
events before and after soft tissue sarcoma diagnosis. 
There are only four published studies, to our knowledge, 
that have investigated VTEs in adult STS patients. Two of 
these are large studies of thromboembolic events among 
cancer patients that include sarcomas as a cancer site [6, 
7]. Khorana et  al. [6] reported results from a retrospec-
tive cohort study (n  =  1,597 sarcoma patients) includ-
ing patients receiving chemotherapy at any one of 115 
University HealthSystem Consortium locations between 
the years of 1995 and 2002. During their first hospitaliza-
tion for neutropenia, 4.8% of sarcoma patients had a VTE. 
Khorana et al. [7] conducted a retrospective cohort study 
(n  =  21,989 sarcoma cases) of the same health consor-
tium and found that 2.9% of sarcoma patients experienced 
a VTE during one hospitalization following cancer diag-
nosis. Results from these two large studies are difficult to 
compare to our incidence proportions for several reasons: 
in these studies, bone sarcomas were included in their sar-
coma category, median age of the sarcoma group was not 
stated, and incidence proportions were based on a VTE 
diagnosis during a single hospitalization. Our analysis eval-
uated incidence proportions and incidence rates (Table 2) 
over the full 12-month period (or death) after diagnosis.
Two studies reported incidence of venous thromboem-
bolic events (VTEs) among soft tissue sarcoma patients, 
specifically [14, 15]. Mitchell et al. [15] conducted a ret-
rospective cohort study of VTE events among trunk/
extremity soft tissue or bone sarcoma patients presenting 
to their unit between 1998 and 2003. Among STS patients 
(n = 158), 5.0% experienced a DVT and 1.3% experienced 
a PE after diagnosis. Damron et al. [14] conducted a ret-
rospective cohort study of patients receiving surgery for 
bone and soft tissue sarcoma of the head, neck, upper 
extremity and lower extremity. There were 120 STS cases 
included and 4.2% of those cases experienced one or 
more VTE following surgery (2.5% DVT and 2.5% PE). 
Incidence proportions from these two studies were lower 
than what we found in our study (10.6% DVT and 3.0% 
PE). Both of these studies, however, were very small and 
had much younger patient populations than ours.
Our study found that STS patients undergoing chemo-
therapy were roughly 50% more likely (DVT: RR =  1.7, 
PE: RR = 1.5, OTE: RR = 1.4) to experience a DVT, PE 
or OTE after diagnosis, although only about 10% of our 
STS patients received chemotherapy treatment (Table 3). 
Damron et  al. [14] reported a similar result; STS 
patients undergoing chemotherapy treatment were at an 
increased risk of VTE compared to those not receiving 
chemotherapy (p = 0.04).
An important component of our analysis was the eval-
uation of VTE history as a risk factor for future VTE 
events. Our results suggest that VTE history is the most 
important factor to consider in evaluating risk of future 
VTE in STS patients. There are no other studies in the 
current literature that quantify the association between 
VTE history and future events among STS patients; how-
ever, this result is consistent with broader studies of VTE 
among cancer patients [16, 17].
The major risk factors for VTEs among cancer patients 
reported in the literature are increased age, female 
sex, African American race, renal disease, infection, 
Table 2 Unadjusted incidence rates of  venous thrombo-
embolic events, before and after STS diagnosis
Rate ratios are highlighted in italics.
a VTE venous thromboembolic events, STS soft tissue sarcoma, DVT deep vein 
thrombosis, PE pulmonary embolism, OTE other thromboembolic event. OTE 
category includes the following diagnoses: central retinal vein occlusion, venous 
tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous 
sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, 
phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/
thrombophlebitis of other sites, gout with other specified manifestations, Budd–
Chiari syndrome, and venous embolism/thrombosis of renal vein.
b n number of VTE events, p-y person-years.
c Rates are per 1,000 person-years and are unadjusted. Age adjustment 
is unnecessary as these rates are intentionally representative of the older 
subpopulation (ages 65+) of STS patients. Only first VTE counted in rate 
estimates.








 n/person‑yearsb 137/3,418 367/2,468
 Rate/1,000c 40.1 (33.7–164.7) 148.7 (133.9–164.7)




 n/person‑yearsb 34/3,463 105/2,589
 Rate/1,000c 9.8 (6.8–49.1) 40.6 (33.2–49.1)




 n/person‑yearsb 82/3,438 106/2,590
 Rate/1,000c 23.9 (19.0–49.5) 40.9 (33.5–49.5)
 Rate ratio (after vs. 
before)d
– 1.7 (1.3–2.3)
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Table 3 Unadjusted incidence rates of venous thromboembolic events after cancer diagnosis among older STS patients
Per SEER-Medicare data use agreement, cell sizes <11 cannot be displayed, nor can estimates that could be used to derive the undisplayed numbers <11. Rate ratios 
are highlighted in italics.
a DVT deep vein thrombosis, PE pulmonary embolism, OTE other thromboembolic event. OTE category includes the following diagnoses: central retinal vein 
occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower 
extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, 
Budd–Chiari syndrome, and venous embolism/thrombosis of renal vein.
b N number of VTE events, P-Y person-years.
c Rates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation 
(≥65 years) of STS patients. Only first VTE counted in rate estimates.
d Rate ratios are unadjusted.
e History of VTE of interest in the 12 months before STS diagnosis.
f History of CVD is defined as a history of any of the following events in the 12 months before STS diagnosis: myocardial infarction, ischemic stroke, onset congestive 
heart failure, angina, or TIA.
g Other/unknown category includes primary sites of the breast, female genital system, other non-epithelial, respiratory system, urinary system, other sites and 
unknown sites.
DVTa PEa OTEa
N/P‑Yb Rate/1,000c (95% CI) N/P‑Yb Rate/1,000c (95% CI) N/P‑Yb Rate/1,000c (95% CI)
By major STS subtype
 Angiosarcoma (n = 184) 14/147 95.4 (52.1, 160.0) <11 26.5 (7.2, 68.0) <11 39.8 (14.6, 86.6)
 Fibrosarcoma (n = 64) <11 72.1 (19.6, 184.5) 0 0 <11 17.6 (0.4, 97.8)
 GIST (n = 845) 94/683 137.6 (111.2, 168.4) 33/721 45.7 (31.5, 64.2) 23/730 31.5 (20.0, 47.3)
 Leiomyosarcoma (n = 264) 19/210 90.6 (54.5, 141.4) <11 28.0 (10.3, 60.8) <11 32.6 (13.1, 67.1)
 Liposarcoma (n = 224) 13/118 110.1 (58.6, 188.2) <11 24.5 (5.1, 71.7) <11 24.5 (5.0, 71.5)
 MFH (n = 184) 20/178 112.2 (68.5, 173.3) <11 21.9 (6.0, 55.9) <11 27.3 (8.9, 63.6)
 Nerve sheath tumor (n = 118) 15/93 160.8 (90.0, 265.3) <11 40.7 (11.1, 104.2) <11 49.8 (16.2, 116.3)
 Sarcoma, NOS (n = 1,422) 166/812 204.4 (174.5, 237.9) 41/862 47.5 (34.1, 64.5) 41/858 47.8 (34.3, 64.8)
By history of VTEe
 Yes 61/51 1199.2 (917.3–1540.5) 11/14 785.5 (392.3–1406.0) 30/50 599.2 (404.3–855.4)
 No 306/2,417 126.6 (112.8–141.6) 94/2,575 27.6 (24.3–31.1) 76/2,540 29.9 (23.6–37.5)
 Rate ratio (yes vs. no)d – 9.5 (7.2–12.5) – 21.5 (11.5–40.2) – 20.0 (13.1–30.6)
By history of CVD eventf
 Yes 120/579 207.3 (171.9–247.9) 29/623 46.6 (31.2–66.9) 39/619 63.1 (44.8–86.2)
 No 247/1,889 130.8 (115.0–148.1) 76/1,966 38.7 (30.5–48.4) 67/1,971 34.0 (26.3–43.2)
 Rate ratio (yes vs. no)d – 1.6 (1.3–2.0) 1.2 (0.8–1.8) 1.9 (1.3–2.8)
By disease stage
 Localized 133/1,236 107.6 (90.1–127.5) 38/1,290 29.5 (20.9–40.4) 34/1,295 26.3 (18.2–36.7)
 Regional 93/586 158.7 (128.1–194.4) 26/614 42.3 (27.7–62.1) 34/610 55.7 (38.6–77.9)
 Distant 86/380 238.9 (191.1–295.0) 25/385 65.0 (42.1–95.9) 19/387 49.1 (29.6–76.7)
 Rate ratio (regional and distant. vs. local)d – 1.5 (1.1–1.9) – 1.4 (0.9–2.4) – 2.1 (1.3–3.4)
By chemotherapy
 Yes 74/324 227.9 (178.9–286.1) 20/348 57.5 (35.1–88.7) 19/346 54.9 (33.0–85.7)
 No 293/2,413 136.7 (121.5–153.3) 85/2,241 37.9 (30.3–46.9) 87/2,244 38.8 (31.1–47.8)
 Rate ratio (yes vs. no)d – 1.7 (1.3–2.2) – 1.5 (0.9–2.5) 1.4 (0.9–2.3)
By surgery of primary tumor
 Yes 247/1,976 125.0 (109.9–141.6) 72/2,065 34.9 (27.3–43.9) 76/2,064 36.8 (29.0–46.1)
 No 115/467 246.4 (203.5–295.8) 32/498 64.2 (43.9–90.7) 29/501 57.9 (38.8–83.1)
 Rate ratio (yes vs. no)d – 0.5 (0.4–0.6) – 0.5 (0.4–0.8) – 0.6 (0.4–1.0)
By Primary site
 Connective/subcutaneous 136/830 163.9 (137.5–193.8) 33/877 37.6 (25.9–52.8) 37/875 42.3 (29.8–58.3)
 Digestive system 120/832 144.2 (119.5–172.4) 38/879 43.2 (30.6–59.4) 29/885 32.8 (22.0–47.1)
 Other/unknowng 111/805 137.8 (113.3–165.9) 34/833 40.8 (28.3–57.0) 40/830 48.2 (34.4–65.7)
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pulmonary disease, obesity, arterial thromboembolism, 
inherited prothrombotic mutations, prior history of 
VTE, performance status, advanced stage cancer, major 
surgery, hospitalization, chemotherapy, hormone ther-
apy, anti-angiogenic agents, erythropoiesis-stimulating 
agents, transfusions, and central venous catheters [7, 12, 
18]. In our predictive models, many of these risk factors 
proved to be predictors of VTEs in the 12 months after 
STS diagnosis.
A few interesting differences are worth discussion. Ath-
erosclerosis was a strong predictor for DVT, PE and OTE 
events in our data. This condition is not generally men-
tioned as a risk factor for VTE among cancer patients; 
however, cardiovascular literature has suggested a link 
between these two conditions [19–22]. We also observed 
that central venous catheterization, high-risk surgery, 
and surgery of primary were associated with a decreased 
risk of DVT after STS diagnosis. Decreased risk in this 
subgroup of patients is likely due to the close monitor-
ing and prophylactic treatment for venous thromboses in 
surgical and catheterization situations.
Finally, our analysis compared the risk of VTE events 
in STS versus non-cancer patients both before and after 
STS diagnosis. Our study found that patients with angio-
sarcoma and sarcoma NOS were more likely to have 
experienced a VTE in the recent past (i.e. 12  month 
before STS diagnosis) than non-cancer individuals. 
These results support the theory that VTE could be a risk 
marker for an ensuing STS diagnosis or, perhaps, a mis-
diagnosis. Several authors of case studies suggested that 
STSs may present as or be mistaken for a VTE, under-
lining the importance of investigating potential tumors 
when diagnosing VTE. In particular, STSs of the lower 
extremities have been misdiagnosed as DVTs [23–26] 
and pulmonary sarcomas/leiomyosarcomas have been 
misdiagnosed as pulmonary embolisms [27–40].
There are several strengths of note for this study. To 
our knowledge, this is the first study to examine VTEs 
among older STS patients. In this analysis we were able 
to focus on STS patients in particular, rather than the 
broader category of sarcoma which includes bone sar-
comas. The STS patient cohort was large (n  =  3,840) 
allowing us to provide data by STS subtype. The wealth 
of the data in the SEER-Medicare database allowed us to 
quantify the occurrence of TE events before STS diagno-
sis and during various time periods after STS diagnosis, 
and to make comparisons between STS patients and age-
matched non-cancer individuals. Furthermore, we were 
able to adjust for and/or stratify by important covariates 
in our analysis. No previous studies performed multivari-
ate analyses on STS patients nor did they investigate the 
timing of VTE events among STS patients.
Table 4 Relative risk of  VTE after  STS diagnosis, recent 
versus no recent VTE history
All models adjusted for age. Recent VTE history = history of VTE in the 
12 months before STS diagnosis. VTE venous thromboembolic event, including 
deep vein thrombosis, pulmonary embolism, and other thromboembolic events. 
The other thromboembolic event category includes the following diagnoses: 
central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic 
thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of 
superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial 
veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with 
other specified manifestations, Budd–Chiari syndrome, and venous embolism/
thrombosis of renal vein.
a Hazard ratios for STS subtypes other than those listed were not estimable due 
to small numbers.
b Maligant fibrous histiocytoma.
c Nerve sheath tumor.
d Sarcoma not otherwise specified.
+ Statistically significant.







Sarcoma NOSd 15.4 (10.9–21.8)+
Table 5 Relative risk of VTEs before and after STS diagno-
sis/index date: STS versus non-cancer cohort
All models adjusted for age at index/diagnosis date. Estimates represent the 
relative risk of VTE event in the 12 months before or after diagnosis/index date. 
STS patients 3,840; non-cancer patients = 3,480. VTE Venous Thromboembolic 
Event (including deep vein thrombosis,pulmonary embolism, and other 
thromboembolic events). OTE category includes the following diagnoses: 
central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic 
thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of 
superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial 
veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with 
other specified manifestations, Budd-Chiari syndrome, and venous embolism/
thrombosis of renal vein.
a Hazard ratios for STS subtypes other than those listed were not estimable due 
to small numbers.
b Maligant fibrous histiocytoma.
c Nerve sheath tumor.
d Sarcoma not otherwise specified.
+ Statistically significant.
STS subtypea Before odds ratio  
(95% CI)
After hazard ratio 
(95% CI)
Angiosarcoma 4.0 (1.4, 11.1)+ 9.1 (2.1, 39.5)+
Fibrosarcoma 0.5 (0.1, 2.0) 1.0 (0.1, 16.0)
GIST 1.0 (0.7, 1.4) 4.0 (2.8, 5.7)+
Leiomyosarcoma 1.5 (0.6, 3.5) 5.5 (2.1, 15.0)+
Liposarcoma Not estimable 2.5 (0.9, 7.6)
MFHb 1.4 (0.6, 3.3) 19.7 (3.7, 106.0)+
NSTc 2.1 (0.8, 5.4) 4.4 (1.1, 17.5)+
Sarcoma NOSd 1.9 (1.4, 2.6)+ 5.2 (3.8, 6.9)+
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As in any study, limitations were present. Many effect 
estimates are imprecise, present with wide confidence 
intervals, and should be interpreted cautiously with the 
direction of the effect emphasized over the magnitude. 
The STS classification of MFH was changed in 2002 
because the large majority of tumors formerly classified 
as MFH can be more meaningfully classified as other 
tumor types. However, due to the timeframe of SEER-
Medicare data collection, the old categorization had to be 
used for this study. The results based on this older cohort 
(i.e., 65 years or older) are generalizable only to those of 
the same age group. Also, information on some behav-
ioral risk factors such as smoking, sedentary lifestyle, 
immobility, and CVD family history was unavailable. 
Finally, we had no access to information about potential 
predictive biomarkers such as elevated platelet or leu-
kocyte counts, tissue factor, soluble p-Selectin, D-dimer, 
factor V Leiden, and prothrombin 20210A mutations [12, 
41, 42].
Conclusion
This is the first study to perform an in depth analysis of 
VTEs among older STS patients. Our results indicate 
that STS patients are at increased risk of VTEs after can-
cer diagnosis and that patients with a history of VTE 
are much more likely to have a subsequent VTE in the 
12 months after their sarcoma diagnosis. VTEs are com-
mon and serious co-morbidities that should be closely 
monitored in older STS patients, particularly during the 
first 3  months after diagnosis and among those with a 
recent history of a VTE.
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